Clinical

  • Clinical Solutions
  • AI solutions portfolio

Explore Aiforia’s comprehensive portfolio of high-performance AI solutions, engineered for both clinical and preclinical applications. Aiforia’s solutions aim to enhance the speed, accuracy, and consistency of analyzing large and complex medical images, especially in pathology.

Learn more

Research

  • Research solutions
  • Aiforia® Create
  • AI solutions portfolio

Aiforia’s research solutions offer fully automated study-centric workflows and pathology image analysis applications that cater to all research areas. Empowered by robust AI capabilities, pathologists and scientists can make discoveries while saving time by automating repetitive tasks – also within the framework of GLP. Aiforia’s solutions can be integrated with any existing laboratory infrastructure to enjoy the full benefits of a digitized workflow.

Learn more

Aiforia® Create is the most versatile tool for developing deep learning AI models for image analysis in digital pathology. Its cloud-based, collaborative working environment allows multiple users to work together in real time, anywhere in the world. Praised for its intuitive user interface, it allows users a fast start, even without any prior AI experience.Learn more >

Learn more

Explore Aiforia’s comprehensive portfolio of high-performance AI solutions, engineered for both clinical and preclinical applications. Aiforia’s solutions aim to enhance the speed, accuracy, and consistency of analyzing large and complex medical images, especially in pathology.

Learn more

AI development tool

  • Aiforia® Create

Aiforia® Create is the most versatile tool for developing deep learning AI models for image analysis in digital pathology. Its cloud-based, collaborative working environment allows multiple users to work together in real time, anywhere in the world. Praised for its intuitive user interface, it allows users a fast start, even without any prior AI experience.

Learn more

Resources

  • Publications
  • Resource Library
  • Press releases

Explore some of our latest publications showcasing the discoveries enabled by the Aiforia® Platform.

Learn more

Aiforia's insights and resources for AI in pathology. View some of our content pieces from the world of AI.

Learn more

Stay updated with Aiforia’s recent announcements. Explore our latest news, updates and announcements.

Learn more

Company

  • About us
  • Investors
  • Partners
  • Media
  • Events
  • Careers
  • Quality and security

Find out more about shareholder matters, investment discussions, and financial-related information.

Learn more

Aiforia's mission is to transform pathology image analysis with AI, enabling better care for each patient. To succeed, we need our trusted partners. Explore Aiforia’s partner network.

Learn more

Experience our AI solutions firsthand. Explore the list of conferences where you can connect with Aiforia’s team live and book a time to discover the future of AI-powered image analysis.

Learn more

Our mission is to transform pathology image analysis with AI, enabling better care for each patient. Find out more about job openings, thesis opportunities, or submitting applications.

Learn more

Aiforia Technologies holds information security to the highest standard. We hold several, globally relevant quality and security certifications, so you can be sure your sensitive information is safe.

Learn more

Research

Research solutions

Aiforia® Create

AI solutions portfolio

AI development tool

Aiforia® Create

Resources

Publications

Resource Library

Press releases

Aiforia releases another CE-IVD marked clinical AI Model — expanding its diagnostic pathology offering to prostate cancer

Aiforia announces the CE-IVD marking of the Aiforia® Clinical AI Model for Prostate Cancer; Gleason Grade Groups.
Written by Aiforia

This latest regulatory certification brings Aiforia’s portfolio of AI-powered diagnostic tools to a total of 5 CE-IVD marked clinical AI models for breast, lung, and now prostate cancer — the most commonly occurring cancer in men.

According to the World Cancer Research Fund, more than 1.4 million new cases of prostate cancer were diagnosed in 2020. Both pathologists and patients deserve reliable and efficient tools for prognostics, diagnostics, and guiding treatment pathways. Gleason grading is the strongest predictor of outcome for the disease.

The latest CE-IVD marked AI model brings automation and consistency to prostate cancer diagnostics. The deep learning-based tool is able to automatically detect and grade tumor areas in prostate tissue images from whole slide images (WSI) to assess Gleason patterns — the most common system for grading prostate cancer. Gleason Grades are assigned to prostate tissue samples to represent how cancerous the tissue is.

“AI solutions will develop to aid prostate cancer diagnostics further, beyond the augmented Gleason grade assessment. Ideally, AI will help in the development of novel ways in patient stratification and treatment decision making, also when histology-based models are combined with other types of data,” explains Dr. Tuomas Mirtti, Consulting Clinical Pathologist and Chief Physician in the Helsinki University Hospital Diagnostic Center in Finland.

“Only a few days ago we announced the release of our CE-IVD marked Aiforia® Clinical AI Model for Breast Cancer; PR. Aiforia is now only one AI model away from reaching its business target; obtaining the CE-IVD marking for 6 AI models intended for clinical diagnostics. We have achieved this versatile portfolio of robust tools for pathologists and pathology labs in the diagnostic support of some of the world’s most common cancers, in just a few short months. I believe this is a testament to the highly skilled team we have at Aiforia,” explains Jukka Tapaninen, CEO of Aiforia Technologies.

Further enquiries

Emma Vehviläinen, CMO, Aiforia Technologies Plc, tel. +358406675204
Jukka Tapaninen, CEO, Aiforia Technologies Plc, tel. +33610416686


https://investors.aiforia.com/